BPMC News and Press, Blueprint Medicines Corporation From 05/03/22

Blueprint Medicines Corporation (BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Offic...

Blueprint Medicines  press release (NASDAQ:BPMC): Q1 GAAP EPS of -$1.79 beats by $0.10. Revenue of $62.73M (+190.7% Y/Y) beats by $22.75M. For further details see: Blueprint Medicines  GAAP EPS of -$1.79 beats by $0.10, revenue of $62.73M beats by $22.75M

Blueprint Medicines Reports First Quarter 2022 Results PR Newswire -- Achieved $23.8 million in AYVAKIT ® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway f...

Blueprint Medicines  (NASDAQ:BPMC) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.85 (-7.6% Y/Y) and the consensus Revenue Estimate is $39.98M (+85.3% Y/Y). Over the last 1 year, BPMC has beaten EPS estimates 50% of...

Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 PR Newswire CAMBRIDGE, Mass. , April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conferenc...

Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...

Blueprint Medicines (NASDAQ:BPMC) on Friday announced a clinical trial supply agreement with AstraZeneca (AZN) under which it will evaluate its investigational agents BLU-945 and BLU-701 in combination with osimertinib in its ongoing SYMPHONY and HARMONY trials, respectively. Blueprint also a...

Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer PR Newswire -- Early dose escalation data show dose-dependent reductions in ctDNA and tumor bur...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blueprint Medicines (NASDAQ: BPMC ): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE: BMY ):  Food and Drug Admi...

The European Commission approved the expanded use of Blueprint Medicines' (NASDAQ:BPMC) Ayvakyt (avapritinib) as a monotherapy for adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least o...